Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). RevMed alleges ERAS-0015 infringes U.S. Patent No. 12,409,225 and involves misappropriated trade secrets.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- RevMed alleges ERAS-0015 infringes U.S. Patent No. 12,409,225 and involves misappropriated trade secrets
- RevMed demanded cessation of U.S. ERAS-0015 activities outside the Hatch-Waxman safe harbor
- Dispute creates potential development delays, litigation costs, licensing needs, or restrictions on ERAS-0015 commercialization
- RevMed also challenged Erasca’s comparative preclinical disclosures involving ERAS-0015 and RMC-6236
- Erasca disputes the allegations and plans to contest them vigorously
Other items in this filing:
- Item 7.01: Regulation FD Disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.